Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$3.34 USD
+0.18 (5.70%)
Updated May 2, 2024 04:00 PM ET
After-Market: $3.34 0.00 (0.00%) 7:50 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Cellectar Biosciences, Inc. [CLRB]
Reports for Purchase
Showing records 41 - 60 ( 120 total )
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
1Q22: Pivotal WM Trial Cleared Recent DMC Futility Review, Cash Thru 1H23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Pivotal WM Trial Positive DMC Futility Review Means Efficacy, in Our View
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
4Q21: Clinical Progress with Iopofosine Across the Board, Funded Into 2H23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
ASH Poster Shows Iopofosine''s Potency in Highly Refractory MM
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Encouraging CLOVER-1 Data at ASH; Awaiting WM Interim Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Iopofosine Showing Promise in Phase 1 Pediatric Brain & Solid Tumor Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Phase 1b Shows Favorable Safety of Inhaled Voriconazole In Asthmatics
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
3Q21: Clinical Progress with Iopofosine Across the Board, Funded Into 2H23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Near-Cash Valuation Completely Unwarranted, Signs Manufacturing Partner
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Eyes on CLOVER-WaM Interim Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
2Q21: Pivotal CLR 131 Results in 3Q22, Sufficiently Funded Into 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J